Companies · HIMS
Hims & Hers
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Aug 10, 2026
Hims & Hers posts $753M Q2 2026 revenue (+40% YoY), raises full-year guide to $3.1-3.3B, and deploys AI-native care platform showing 3x engagement uplift and 50% nonclinical task reduction.
Hims & Hers accelerated domestic revenue growth to 16% YoY in Q2 2026 while international revenue surged to $131 million following the Eucalyptus acquisition, together driving total quarterly revenue above $753 million and prompting a full-year revenue guidance raise to $3.1-3.3 billion. The company's AI-native care platform — deployed first to Hers weight loss customers — is already generating measurable operational leverage: 3x message engagement, 50% reduction in nonclinical support tasks, and early cancellation rate improvements that management expects to compound into stronger LTV and margin expansion within 12-18 months. The FTC complaint filed July 29 and $81 million in nonrecurring costs (acquisition, restructuring, legal) are the primary near-term risk, though management is contesting vigorously and characterizes the costs as one-time.
Tone: bullishRevenue
$2.3B
HIMS 10-K · FY 2025
Employees
2,442
Revenue growth YoY
+59%
Founded
2017
Profile
HIMS 10-K Item 1 · Feb 23, 2026Hims & Hers is a consumer-first digital health and wellness platform that connects patients to licensed healthcare providers via telehealth, fulfills prescriptions through its own licensed pharmacies, and sells prescription and non-prescription products via subscription. The company operates across sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, serving customers in the United States, Canada, the United Kingdom, and the European Union. Its integrated model spans provider network, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities.
Read filing description ↓ Collapse description ↑
Hims & Hers Health, Inc. has built a consumer-first platform transforming the way customers fulfill their health and wellness needs. We believe that the Company has the technical infrastructure, distributed provider network, and access to clinical capabilities to lead the migration of routine office visits to a personalized, digital, accessible format. The Hims & Hers platforms include access to a highly-qualified and technologically-innovative provider network, an electronic medical record system designed to support providers and customers, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Our digital platform enables access to treatments for a broad range of chronic conditions, including those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. Hims & Hers connects patients to licensed healthcare professionals who can prescribe medications when appropriate, including through personalized treatment plans, with prescriptions fulfilled online through licensed pharmacies. In addition, we also offer access to a range of non-prescription health and wellness products. Through the Hims & Hers mobile applications, consumers can access a range of educational programs, wellness content, community support, and other services that promote lifelong health and wellness. Since our founding, we have facilitated over fifty million telehealth consultations, enabling greater access to high-quality, convenient, affordable, personalized care for people in the United States, Canada, the United Kingdom, and the European Union.
Primary products
- Prescription medications (generic, brand-name, and compounded)
- Compounded GLP-1 products
- Over-the-counter drug and device products
- Cosmetics and supplement products
- Telehealth consultations
- Laboratory testing services
End markets
Geographies
Named customers
“While we believe there are currently no direct competitors that offer the full suite of solutions and direct-to-consumer touch points as we do, there are several companies that offer components of telehealth or address conditions that compete with our solutions.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Revenue increased $871.1 million, or 59%, in 2025 versus 2024, driven primarily by growth in weight loss offerings and the addition of new subscribers.
The rest of HIMS is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.